ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
1. 7ÔÂ22ÈÕ£¬CDEÏÔʾ£¬¿Òò¿Æ¼¼Ò»¿îÓÃÓÚÂýÐÔÒÒÐ͸ÎÑ×ÖÎÁƵÄÔÚÑÐÒ©Îï KW-040×¢ÉäÒºÁÙ´²ÊÔÑéÉêÇë»ñĬʾÔÊÐí¡£KW-040×¢ÉäÒºÊÇ¿Òò¿Æ¼¼ÁªºÏ°²ÁúÉúÎ↑·¢ÓÃÓÚÂýÐÔÒÒÐ͸ÎÑ×ÖÎÁƵÄÒ»¿îsiRNA Ò©Îï¡£
2. 7ÔÂ22ÈÕ£¬CDE¹ÙÍø¹«Ê¾£¬Telix PharmaceuticalsÉ걨µÄ1ÀàÐÂÒ©177Lu-HuJ591µ¥¿¹×¢ÉäÒº»ñÅúÁÙ´²£¬Ä⿪·¢ÖÎÁƼÈÍù½ÓÊܹýÐÛ¼¤ËØÊÜÌåͨ·ÒÖÖÆ¼Á£¨ARPI£©ÖÎÁÆÏ£ÍûµÄǰÏßÏÙÌØÒìÐÔĤ¿¹Ô£¨PSMA£©ÑôÐÔ×ªÒÆÐÔÈ¥ÊÆ¶Ô¿¹ÐÔǰÏßÏÙ°©£¨mCRPC£©»¼Õß¡£
3. 7ÔÂ22ÈÕ£¬ÉÆÍåÉúÎïÐû²¼£¬¹«Ë¾×ÔÖ÷¿ª·¢µÄ×¢ÉäÓô×ËáÁÁ±ûÈðÁÖ»ìÐüÒº(SW-001) ÍíÆÚǰÏßÏÙ°©IIIÆÚÁÙ´²ÊÔÑéINDÉêÇëͨ¹ý¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÅú×¼¡£SW-001ÊÇÒ»¿î»ùÓÚÔλÄý½ºÖƼÁÊÖÒյĴ×ËáÁÁ±ûÈðÁÖ³¤Ð§»º¿ØÊÍÖÆ¼Á£¬ÆäÔÚÍíÆÚǰÏßÏÙ°©µÄÖÎÁÆÉÏ£¬Ó뺣ÄÚÒÑÉÏÊд×ËáÁÁ±ûÈðÁÖ³¤Ð§²úÆ·Ïà±È¾ßÓÐÏÔÖøµÄÁÙ´²ÓÅÊÆ¡£
4. 7ÔÂ21ÈÕ£¬ÏÈÉùÒ©Òµ¼¯ÍÅ£¨2096.HK£©ÆìÏÂÁ¢ÒìÒ©ÆóÏÈÉùÔÙÃ÷Ðû²¼£¬Æä×ÔÖ÷Ñз¢µÄ°ÐÏòFGFR2bµÄ¿¹ÌåżÁªÒ©ÎADC£©SIM0686µÄÁÙ´²ÊÔÑéÉêÇ루IND£©»ñÃÀ¹úFDAÅú×¼¡££¬ÎªÈ«ÇòÓÈÆäÊÇÖйú¸ß·¢µÄθ°©µÈʵÌåÁö»¼ÕßÌṩÁËDZÔÚµÄÐÂÖÎÁƼƻ®¡£
1. 7ÔÂ22ÈÕ£¬Èüŵ·Æ£¨Sanofi£©½ñÈÕÐû²¼ÒѸ濢ÐÒ飬½«ÊÕ¹º×ܲ¿Î»ÓÚÓ¢¹úÂ׶صÄ˽ӪÉúÎïÊÖÒÕ¹«Ë¾VicebioÓÐÏÞ¹«Ë¾£¨¡°Vicebio¡±£©¡£´Ë´ÎÊÕ¹º½«ÎªÈüŵ·Æ´øÀ´Ò»¿î´¦ÓÚÔçÆÚ½×¶Î¡¢Õë¶ÔºôÎüµÀºÏ°û²¡¶¾£¨RSV£©ºÍÈËÆ«·Î²¡¶¾£¨hMPV£©ÕâÁ½ÖÖºôÎüµÀ²¡¶¾µÄÁªºÏÒßÃçºòÑ¡²úÆ·£¬²¢½èÖúVicebioµÄ¡°·Ö×Óǯ¡±£¨Molecular Clamp£©ÊÖÒÕ£¬ÔöÇ¿×ÔÉíÔÚÒßÃçÉè¼ÆÓ뿪·¢·½ÃæµÄÄÜÁ¦¡£
1. 7ÔÂ16ÈÕ£¬Î÷°àÑÀ¿¨Âå˹ÈýÊÀ¹ú¼ÒÐÄѪ¹ÜÑо¿ÖÐÐĵÄÑо¿Ö°Ô±ÔÚ¹ú¼Ê¶¥¼âѧÊõÆÚ¿¯ Nature ÉϽÒÏþÁËÌâΪ£ºImidazole propionate is a driver and therapeutic target in atherosclerosis µÄÑо¿ÂÛÎÄ¡£¸ÃÑо¿·¢Ã÷£¬³¦µÀϸ¾úµÄÒ»ÖÖ´úлÎïßäßò±ûËᣨImidazole Propionate£¬ImP£©»áÔö½ø¶¯ÂöÖàÑùÓ²»¯µÄÉú³¤£¬´Ó¶øÎªÐÄѪ¹Ü¼²²¡µÄÔçÆÚ¼ì²â¡¢Ô¤·ÀºÍ¸öÐÔ»¯ÖÎÁÆÌṩÁËае㡣
[1]Mastrangelo, A., Robles-Vera, I., Ma?anes, D. et al. Imidazole propionate is a driver and therapeutic target in atherosclerosis. Nature (2025). https://doi.org/10.1038/s41586-025-09263-w